Methotrexate should not be used for patients with end-stage kidney disease

Acta Clinica Belgica

Volumn 61, Issue 4, 2006, Pages 166-169

  Boey, Olivier ^a   Van Hooland, S ^a   Woestenburg, A ^a   Van Der Niepen, P ^a   Verbeelen, D ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Intoxication; Low dose methotrexate; Psoriasis; Renal failure

Indexed keywords

ANTIRHEUMATIC AGENT; CIPROFLOXACIN; ELVORINE; FLUCONAZOLE; FOLINIC ACID; METHOTREXATE; NYSTATIN; PERFLUOROBUTYLTETRAHYDROFURAN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AGED; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; ENDOSCOPY; ESOPHAGUS CANDIDIASIS; GASTROINTESTINAL TOXICITY; HEPATOMEGALY; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; PNEUMONIA; RHEUMATOID ARTHRITIS; SORE THROAT;

EID: 33750046010     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2006.028     Document Type: Article

References (16)

1. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000; 14:382-388.
2. American College of Rheumatology. Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring, drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996; 39: 723-31.
3. Physicians Desk Reference. Methotrexate sodium tablets, methotrexate sodium for injection, methotrexate LPF sodium and methotrexate sodium injection. 53 rd ed. Montvale (NJ): Medical Economics; 1999: 1397-401.
4. Ellman MH, Hou S, Ginsberg D. Low-dose methotrexate and severe neutropenia in patient undergoing renal dialysis. Arthritis Rheum. 1990; 33: 1060-1061.
5. Nakamura M, Sakemi T, Nagasawa K. Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Reumatol. 1999; 26: 1424-1425.
6. Chatham WW, Morgan SL, Alarcon G.S. Renal failure: a risk factor for methotrexate toxicity. Arthritis Rheum. 2000; 43: 1185-1186.
7. Boulanger H, Launay-Vacher V, Hierniaux P, Fau JB, Deray G. Severe methtotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis. Nephrol Dial Transplant 2001; 16: 1087.
8. Basile C, Montanaro A, Semeraro A. Should low-dose methotrexate therapy be prescribed to dialysis patients? Nephrol Dial Transplant 2002; 17: 530-531.
9. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998; 5: 277-292.
10. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology 2000; 2-3: 247-257.
11. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics in rheumatoid arthritis patients. Ann Rheum Dis. 1998; 57: 110-113.
12. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996; 30: 194-210.
13. McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am. 1997; 4: 939-954.
14. Hoekstra M, van Ede AE, Haagsma CJ et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003; 62: 423-426.
15. Ahmad S, Shen FH, Bleter WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med 1978; 138: 1146-1147.
16. Wall SM, Johansen MJ, Molony DA, Dubose TD Jr, Jaffa N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996; 28 (6): 846-54.